Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Abstract: A method for producing ACE Inhibitor peptides from a protein source or plasma is disclosed. The method utilizes proteolysis by intestinal, blood-circulating, or membrane-bound proteases. The initial synthesis step could require obtaining a protein source either from a human or animal. A protease is added to either a given plasma protein or plasma and incubated. Following incubation, the protease activity must be quenched using a protease inhibitor to inactivate the protease. After incubation with protease inhibitor, the solution will contain a mixture of bioactive ACE inhibitory peptides and inert peptides. This mixture may be purified to select for the ACE inhibitory peptides through centrifugation. The mixture may also be sterilized to remove any microbial contaminants. The ACE inhibitory peptides can be mixed with protein powders, incorporated into baked good and put into other food products to provide food products with the added benefit of lowering blood pressure.

Abstract: The disclosure concerns a class of hemoglobin based oxygen carriers (HBOCs) comprising a first hemoglobin protein cross-linked by a chemical reaction that is followed by a strain-promoted alkyne-azide cycloaddition (SPAAC) reaction or by a strain-promoted alkyne-nitrone cycloaddition (SPANC) in the absence of added copper salts to a second modified cross-linked hemoglobin protein. The resulting construct is an HBOC that is capable of binding oxygen and releasing same in a useful manner upon addition in an appropriate solution to the circulatory system of a patient. The disclosure also concerns a method of production of the HBOC where a first and second hemoglobin protein are produced by covalently linking hemoglobin to an angle strained cycloalkyne moiety.

Abstract: Provided are methods of selecting a treatment for a cancer in a subject in need thereof, by analyzing activity of Yes associated protein 1 (YAP) in cancer cells of the subject, and methods of treating cancer using a therapeutically effective amount of an caspase-3 inhibitor. Also provided are methods of improving wound healing by administering a wound healing effective amount of a caspase-3 activator.

Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

Abstract: Voltage reporter molecules and compositions, and methods for detecting voltage and voltage change in cells are provided. Also provided are methods for delivery, expression, and use of the voltage reporter molecules in cells, tissues, and subjects.

Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Abstract: The invention discloses a method for the preparation of a peptide by liquid phase coupling of two fragments, an N-terminal fragment and a C-terminal fragment of the desired peptide, wherein the C-terminal fragment is protected on its C-terminal COOH by a psWang linker; the method is demonstrated with liraglutide wherein the C-terminal fragment carries the Palmitoyl-Glu-OtBu residue on the Lys.

Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.

Abstract: The present invention relates to an antimicrobial peptide having an improved antibacterial effect through glutamic acid substitution and, more specifically, to a use of the antimicrobial peptide as an active ingredient in an antibacterial pharmaceutical composition, a food additive, a feed additive, an antiseptic composition, and an antibacterial quasi-drug composition. Not only does the antimicrobial peptide of the present invention exhibit significant antibacterial activity against gram-negative bacteria, but it also exhibits a significant synergistic effect when combinedly treated with antibiotics which have strong antibacterial activity only against gram-positive bacteria and has no or low antibacterial activity against gram-negative bacteria, thereby exhibiting excellent antibacterial effects on gram-positive bacteria, E. coli and Acinetobacter bacteria among gram-negative bacteria, and antibiotic-resistant strains thereof.

Abstract: An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.

Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Abstract: The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.

Abstract: Novel compounds of N-Lipoic-amino acid, N-Lipoic-peptides and their derivatives are described. Also described are compositions and method of compositions containing the derivatives of the amino acids or peptides, and their uses including treating and preventing dermatological or cosmetic conditions or other disorders of the cutaneous system. Compositions and methods of using the compositions for skin lightening and cosmetics are also disclosed.

Abstract: Described herein are membrane permeabilizing peptides, polynucelotides encoding the peptides, and lipid vesicles comprising the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and lipid vesicles for research, diagnosis, disease prevention, and therapeutic treatment.

Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.

Abstract: The present invention discloses a method of treating cancer cells. The method comprises administrating a composition comprises a rhodamine or rhodamine derivative conjugated to a peptide comprises an amino acid sequence of SEQ ID NO: 1 to a subject in need, and activate the composition with light.

Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.

Abstract: The present invention refers to a method for preparing a glucagon-like peptide, comprising precipitation of the peptide or of a precursor peptide by means of mixing with an anti-solvent comprising diisopropyl ether and acetonitrile. Further, the present invention also relates to a peptide conjugated to a solid phase and a pharmaceutical composition comprising a Liraglutide peptide obtainable from a method according to the present invention.

Abstract: The invention concerns a synthetic compound for enabling transfection of eukaryotic cells by means of an amphiphilic block copolymer which synthetic compound comprises a peptide residue having at least one targeting sequence and a nucleic acid binding sequence which nucleic acid binding sequence comprises or consists of at least four consecutive amino acid residues which are positively charged at pH 7.4, wherein the targeting sequence is any sequence that causes a direction of the sequence to a position or a structure inside or on the surface of eukaryotic cells, characterized in that the synthetic compound further comprises a hydrophobic moiety covalently linked to the peptide residue, wherein the hydrophobic moiety comprises or consists of lipoic acid residue, lipoamide residue, a tetradecyl residue, a cholesteryl residue, or a further peptide residue having a sequence with more than 40% amino acid residues with hydrophobic side chains.